Clinical trialNCT05473910RecruitingPhase 1Interventional

A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

SponsorTScan Therapeutics, Inc.Enrollment310AMLMDS

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Shrikanta Chattopadhyay, MD
Tscan Therapeutics
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope
Duarte, California, United States
Monzr Al Malki, MD
Recruiting
University of Colorado - Anschutz Cancer Center
Aurora, Colorado, United States
Mathew Angelos, MD
Recruiting
Scri - Colorado Blood Cancer Institute
Denver, Colorado, United States
Marcello Rotta, MD
Recruiting
Yale
New Haven, Connecticut, United States
Lohith Gowda, MD
Recruiting
Memorial Cancer Institute
Hollywood, Florida, United States
Hugo Fernandez, MD
Recruiting
Moffitt Cancer Institute
Tampa, Florida, United States
Nelli Bejanyan, MD
Recruiting
Northside Hospital
Atlanta, Georgia, United States
Melhem M Solh, MD
Recruiting
Johns Hopkins University
Baltimore, Maryland, United States
Tania Jain, MD
Recruiting
Dana-Farber Cancer Institute - Hematology/oncology
Boston, Massachusetts, United States
Mahasweta Gooptu, MD
Recruiting
Mass General Hospital
Boston, Massachusetts, United States
Yi-Bin Chen, MD
Recruiting
Karmanos Cancer Institute
Detroit, Michigan, United States
Recruiting
Hackensack University Medical Center
Hackensack, New Jersey, United States
Recruiting
Columbia University
New York, New York, United States
Recruiting
Mount Sinai
New York, New York, United States
Alla Keyzner, MD
Recruiting
University North Carolina
Chapel Hill, North Carolina, United States
Anson Snow, MD
Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Saar Gill, MD
Recruiting
Scri - Tristar Bone Marrow Transplant
Nashville, Tennessee, United States
Jeremy Pantin, MD
Recruiting
St. David'S South Austin Medical Center
Austin, Texas, United States
Uttam Rao, MD
Recruiting
Baylor University Medical Center
Dallas, Texas, United States
Luis Pineiro, MD
Recruiting
Md Anderson
Houston, Texas, United States
Uday Popat, MD
Recruiting
Froedert and Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Sameem Abedin, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

SOC + TSC-100SOC + TSC-101

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Nov 2022
Primary completion: 1 Jun 2026
Completion: 30 Jun 2028
Last update posted: 21 Jul 2026
Registered enrollment: 310
Registry id: NCT05473910

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.